Back to Search
Start Over
Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
- Source :
-
Leukemia [Leukemia] 2022 Nov; Vol. 36 (11), pp. 2743-2747. Date of Electronic Publication: 2022 Sep 13. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 1476-5551
- Volume :
- 36
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 36100641
- Full Text :
- https://doi.org/10.1038/s41375-022-01699-7